nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—MAPK11—CXCR3-mediated signaling events—CXCL11—nasal cavity cancer	0.0331	0.0331	CbGpPWpGaD
Nilotinib—BRAF—Frs2-mediated activation—FRS2—nasal cavity cancer	0.027	0.027	CbGpPWpGaD
Nilotinib—TEK—SHP2 signaling—FRS2—nasal cavity cancer	0.027	0.027	CbGpPWpGaD
Nilotinib—BRAF—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.0254	0.0254	CbGpPWpGaD
Nilotinib—MAPK8—Signaling events regulated by Ret tyrosine kinase—FRS2—nasal cavity cancer	0.024	0.024	CbGpPWpGaD
Nilotinib—MAPK14—CXCR3-mediated signaling events—CXCL11—nasal cavity cancer	0.0236	0.0236	CbGpPWpGaD
Nilotinib—MAPK8—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.0188	0.0188	CbGpPWpGaD
Nilotinib—BRAF—Negative regulation of FGFR signaling—FRS2—nasal cavity cancer	0.0185	0.0185	CbGpPWpGaD
Nilotinib—MAPK11—Signalling to ERKs—FRS2—nasal cavity cancer	0.0173	0.0173	CbGpPWpGaD
Nilotinib—BRAF—Signalling to ERKs—FRS2—nasal cavity cancer	0.0172	0.0172	CbGpPWpGaD
Nilotinib—PDGFRA—Allograft Rejection—CXCL11—nasal cavity cancer	0.0157	0.0157	CbGpPWpGaD
Nilotinib—MAPK11—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.015	0.015	CbGpPWpGaD
Nilotinib—MAPK8—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.0147	0.0147	CbGpPWpGaD
Nilotinib—MAPK14—Signalling to ERKs—FRS2—nasal cavity cancer	0.0124	0.0124	CbGpPWpGaD
Nilotinib—MAPK11—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.0117	0.0117	CbGpPWpGaD
Nilotinib—MAPK14—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Nilotinib—PDGFRB—SHP2 signaling—FRS2—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Nilotinib—MAPK14—FGF signaling pathway—FRS2—nasal cavity cancer	0.0105	0.0105	CbGpPWpGaD
Nilotinib—ABL1—Neurotrophic factor-mediated Trk receptor signaling—FRS2—nasal cavity cancer	0.01	0.01	CbGpPWpGaD
Nilotinib—KIT—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00915	0.00915	CbGpPWpGaD
Nilotinib—PDGFRA—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00866	0.00866	CbGpPWpGaD
Nilotinib—LCK—SHP2 signaling—FRS2—nasal cavity cancer	0.00858	0.00858	CbGpPWpGaD
Nilotinib—MAPK8—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00843	0.00843	CbGpPWpGaD
Nilotinib—MAPK14—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.00837	0.00837	CbGpPWpGaD
Nilotinib—KIT—PI-3K cascade—FRS2—nasal cavity cancer	0.00824	0.00824	CbGpPWpGaD
Nilotinib—KIT—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00804	0.00804	CbGpPWpGaD
Nilotinib—MAP2K5—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00801	0.00801	CbGpPWpGaD
Nilotinib—KIT—GAB1 signalosome—FRS2—nasal cavity cancer	0.00798	0.00798	CbGpPWpGaD
Nilotinib—PDGFRB—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0078	0.0078	CbGpPWpGaD
Nilotinib—PDGFRA—PI-3K cascade—FRS2—nasal cavity cancer	0.0078	0.0078	CbGpPWpGaD
Nilotinib—KIT—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.0078	0.0078	CbGpPWpGaD
Nilotinib—PDGFRA—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00761	0.00761	CbGpPWpGaD
Nilotinib—PDGFRA—GAB1 signalosome—FRS2—nasal cavity cancer	0.00755	0.00755	CbGpPWpGaD
Nilotinib—PDGFRA—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00738	0.00738	CbGpPWpGaD
Nilotinib—MAPK8—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00715	0.00715	CbGpPWpGaD
Nilotinib—PDGFRB—PI-3K cascade—FRS2—nasal cavity cancer	0.00703	0.00703	CbGpPWpGaD
Nilotinib—PDGFRB—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00686	0.00686	CbGpPWpGaD
Nilotinib—PDGFRB—GAB1 signalosome—FRS2—nasal cavity cancer	0.00681	0.00681	CbGpPWpGaD
Nilotinib—PDGFRB—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00665	0.00665	CbGpPWpGaD
Nilotinib—BLK—B Cell Activation—FRS2—nasal cavity cancer	0.00661	0.00661	CbGpPWpGaD
Nilotinib—LYN—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00651	0.00651	CbGpPWpGaD
Nilotinib—LCK—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00626	0.00626	CbGpPWpGaD
Nilotinib—KIT—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00616	0.00616	CbGpPWpGaD
Nilotinib—BRAF—Signaling by FGFR—FRS2—nasal cavity cancer	0.00605	0.00605	CbGpPWpGaD
Nilotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00602	0.00602	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.00595	0.00595	CbGpPWpGaD
Nilotinib—KIT—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00589	0.00589	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00583	0.00583	CbGpPWpGaD
Nilotinib—KIT—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0058	0.0058	CbGpPWpGaD
Nilotinib—BRAF—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00564	0.00564	CbGpPWpGaD
Nilotinib—LCK—PI-3K cascade—FRS2—nasal cavity cancer	0.00564	0.00564	CbGpPWpGaD
Nilotinib—PDGFRA—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00558	0.00558	CbGpPWpGaD
Nilotinib—KIT—Downstream signal transduction—FRS2—nasal cavity cancer	0.00554	0.00554	CbGpPWpGaD
Nilotinib—KIT—Signaling by FGFR—FRS2—nasal cavity cancer	0.00551	0.00551	CbGpPWpGaD
Nilotinib—LCK—PI3K/AKT activation—FRS2—nasal cavity cancer	0.0055	0.0055	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00549	0.00549	CbGpPWpGaD
Nilotinib—KIT—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00548	0.00548	CbGpPWpGaD
Nilotinib—LCK—GAB1 signalosome—FRS2—nasal cavity cancer	0.00546	0.00546	CbGpPWpGaD
Nilotinib—KIT—DAP12 signaling—FRS2—nasal cavity cancer	0.00546	0.00546	CbGpPWpGaD
Nilotinib—KIT—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00538	0.00538	CbGpPWpGaD
Nilotinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00534	0.00534	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00525	0.00525	CbGpPWpGaD
Nilotinib—PDGFRA—Downstream signal transduction—FRS2—nasal cavity cancer	0.00524	0.00524	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by FGFR—FRS2—nasal cavity cancer	0.00522	0.00522	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00519	0.00519	CbGpPWpGaD
Nilotinib—PDGFRA—DAP12 signaling—FRS2—nasal cavity cancer	0.00517	0.00517	CbGpPWpGaD
Nilotinib—LYN—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00514	0.00514	CbGpPWpGaD
Nilotinib—KIT—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00513	0.00513	CbGpPWpGaD
Nilotinib—KIT—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00513	0.00513	CbGpPWpGaD
Nilotinib—KIT—DAP12 interactions—FRS2—nasal cavity cancer	0.00513	0.00513	CbGpPWpGaD
Nilotinib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00509	0.00509	CbGpPWpGaD
Nilotinib—KIT—Signaling by EGFR—FRS2—nasal cavity cancer	0.00509	0.00509	CbGpPWpGaD
Nilotinib—KIT—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00504	0.00504	CbGpPWpGaD
Nilotinib—MAPK11—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00504	0.00504	CbGpPWpGaD
Nilotinib—PDGFRB—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00503	0.00503	CbGpPWpGaD
Nilotinib—KIT—Signaling by PDGF—FRS2—nasal cavity cancer	0.00502	0.00502	CbGpPWpGaD
Nilotinib—BRAF—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.005	0.005	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00495	0.00495	CbGpPWpGaD
Nilotinib—MAPK8—Signaling by NGF—FRS2—nasal cavity cancer	0.00487	0.00487	CbGpPWpGaD
Nilotinib—PDGFRA—DAP12 interactions—FRS2—nasal cavity cancer	0.00486	0.00486	CbGpPWpGaD
Nilotinib—PDGFRA—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00486	0.00486	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00486	0.00486	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by EGFR—FRS2—nasal cavity cancer	0.00482	0.00482	CbGpPWpGaD
Nilotinib—MAPK14—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00479	0.00479	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00477	0.00477	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by PDGF—FRS2—nasal cavity cancer	0.00475	0.00475	CbGpPWpGaD
Nilotinib—KIT—B Cell Activation—FRS2—nasal cavity cancer	0.00475	0.00475	CbGpPWpGaD
Nilotinib—PDGFRB—Downstream signal transduction—FRS2—nasal cavity cancer	0.00472	0.00472	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by FGFR—FRS2—nasal cavity cancer	0.0047	0.0047	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00468	0.00468	CbGpPWpGaD
Nilotinib—PDGFRB—DAP12 signaling—FRS2—nasal cavity cancer	0.00465	0.00465	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling by NGF—FRS2—nasal cavity cancer	0.00463	0.00463	CbGpPWpGaD
Nilotinib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00459	0.00459	CbGpPWpGaD
Nilotinib—KIT—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00455	0.00455	CbGpPWpGaD
Nilotinib—PDGFRA—B Cell Activation—FRS2—nasal cavity cancer	0.0045	0.0045	CbGpPWpGaD
Nilotinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00438	0.00438	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00438	0.00438	CbGpPWpGaD
Nilotinib—PDGFRB—DAP12 interactions—FRS2—nasal cavity cancer	0.00438	0.00438	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by EGFR—FRS2—nasal cavity cancer	0.00434	0.00434	CbGpPWpGaD
Nilotinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0043	0.0043	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.0043	0.0043	CbGpPWpGaD
Nilotinib—LYN—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00429	0.00429	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by PDGF—FRS2—nasal cavity cancer	0.00428	0.00428	CbGpPWpGaD
Nilotinib—LCK—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00421	0.00421	CbGpPWpGaD
Nilotinib—PDGFRB—B Cell Activation—FRS2—nasal cavity cancer	0.00405	0.00405	CbGpPWpGaD
Nilotinib—LCK—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00403	0.00403	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00397	0.00397	CbGpPWpGaD
Nilotinib—LYN—B Cell Activation—FRS2—nasal cavity cancer	0.00397	0.00397	CbGpPWpGaD
Nilotinib—MAPK11—Signaling by NGF—FRS2—nasal cavity cancer	0.00388	0.00388	CbGpPWpGaD
Nilotinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00388	0.00388	CbGpPWpGaD
Nilotinib—BRAF—Signaling by NGF—FRS2—nasal cavity cancer	0.00384	0.00384	CbGpPWpGaD
Nilotinib—LCK—Downstream signal transduction—FRS2—nasal cavity cancer	0.00379	0.00379	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR—FRS2—nasal cavity cancer	0.00377	0.00377	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00375	0.00375	CbGpPWpGaD
Nilotinib—LCK—DAP12 signaling—FRS2—nasal cavity cancer	0.00373	0.00373	CbGpPWpGaD
Nilotinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00368	0.00368	CbGpPWpGaD
Nilotinib—MAPK14—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0036	0.0036	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00351	0.00351	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—FRS2—nasal cavity cancer	0.00351	0.00351	CbGpPWpGaD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00351	0.00351	CbGpPWpGaD
Nilotinib—KIT—Signaling by NGF—FRS2—nasal cavity cancer	0.0035	0.0035	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR—FRS2—nasal cavity cancer	0.00348	0.00348	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00345	0.00345	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—FRS2—nasal cavity cancer	0.00344	0.00344	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by NGF—FRS2—nasal cavity cancer	0.00331	0.00331	CbGpPWpGaD
Nilotinib—LCK—B Cell Activation—FRS2—nasal cavity cancer	0.00325	0.00325	CbGpPWpGaD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00311	0.00311	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—FRS2—nasal cavity cancer	0.00306	0.00306	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—FRS2—nasal cavity cancer	0.00298	0.00298	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—FRS2—nasal cavity cancer	0.00278	0.00278	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—FRS2—nasal cavity cancer	0.00277	0.00277	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—FRS2—nasal cavity cancer	0.00277	0.00277	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00267	0.00267	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—FRS2—nasal cavity cancer	0.00239	0.00239	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—FRS2—nasal cavity cancer	0.00221	0.00221	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—FRS2—nasal cavity cancer	0.00199	0.00199	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—FRS2—nasal cavity cancer	0.00192	0.00192	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—FRS2—nasal cavity cancer	0.00189	0.00189	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—FRS2—nasal cavity cancer	0.00181	0.00181	CbGpPWpGaD
Nilotinib—HCK—Immune System—FRS2—nasal cavity cancer	0.00178	0.00178	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CXCL11—nasal cavity cancer	0.00177	0.00177	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—FRS2—nasal cavity cancer	0.0017	0.0017	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CXCL11—nasal cavity cancer	0.00169	0.00169	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—FRS2—nasal cavity cancer	0.00167	0.00167	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—FRS2—nasal cavity cancer	0.00166	0.00166	CbGpPWpGaD
Nilotinib—HCK—Disease—FRS2—nasal cavity cancer	0.00165	0.00165	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—FRS2—nasal cavity cancer	0.00163	0.00163	CbGpPWpGaD
Nilotinib—BLK—Immune System—FRS2—nasal cavity cancer	0.00162	0.00162	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—FRS2—nasal cavity cancer	0.00162	0.00162	CbGpPWpGaD
Nilotinib—FGR—Immune System—FRS2—nasal cavity cancer	0.00161	0.00161	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—FRS2—nasal cavity cancer	0.0016	0.0016	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—FRS2—nasal cavity cancer	0.00158	0.00158	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CXCL11—nasal cavity cancer	0.00141	0.00141	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CXCL11—nasal cavity cancer	0.0014	0.0014	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—FRS2—nasal cavity cancer	0.00137	0.00137	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00131	0.00131	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—FRS2—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCL11—nasal cavity cancer	0.00127	0.00127	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL11—nasal cavity cancer	0.00121	0.00121	CbGpPWpGaD
Nilotinib—BRAF—Disease—FRS2—nasal cavity cancer	0.00118	0.00118	CbGpPWpGaD
Nilotinib—KIT—Immune System—FRS2—nasal cavity cancer	0.00116	0.00116	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—FRS2—nasal cavity cancer	0.0011	0.0011	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL11—nasal cavity cancer	0.00109	0.00109	CbGpPWpGaD
Nilotinib—KIT—Disease—FRS2—nasal cavity cancer	0.00107	0.00107	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL11—nasal cavity cancer	0.00106	0.00106	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FRS2—nasal cavity cancer	0.00105	0.00105	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—FRS2—nasal cavity cancer	0.00102	0.00102	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL11—nasal cavity cancer	0.00101	0.00101	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FRS2—nasal cavity cancer	0.000994	0.000994	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FRS2—nasal cavity cancer	0.000991	0.000991	CbGpPWpGaD
Nilotinib—LYN—Immune System—FRS2—nasal cavity cancer	0.00097	0.00097	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FRS2—nasal cavity cancer	0.000966	0.000966	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FRS2—nasal cavity cancer	0.00092	0.00092	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FRS2—nasal cavity cancer	0.000915	0.000915	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL11—nasal cavity cancer	0.000872	0.000872	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FRS2—nasal cavity cancer	0.000833	0.000833	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FRS2—nasal cavity cancer	0.000825	0.000825	CbGpPWpGaD
Nilotinib—LCK—Immune System—FRS2—nasal cavity cancer	0.000795	0.000795	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FRS2—nasal cavity cancer	0.000751	0.000751	CbGpPWpGaD
Nilotinib—LCK—Disease—FRS2—nasal cavity cancer	0.000734	0.000734	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FRS2—nasal cavity cancer	0.000711	0.000711	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FRS2—nasal cavity cancer	0.000641	0.000641	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FRS2—nasal cavity cancer	0.000627	0.000627	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FRS2—nasal cavity cancer	0.000595	0.000595	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FRS2—nasal cavity cancer	0.000514	0.000514	CbGpPWpGaD
